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
Summary
Sodium-glucose co-transporter 2 inhibitors: their role in heart failure management in Emergency Departments
Pere Llorens1,2
Affiliation of the authors
1Servicio de Urgencias, Unidad de Estancia Corta y Hospitalización a Domicilio, Hospital Doctor Balmis de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Universidad Miguel Hernández, Alicante, Spain. 2Coordinador de Grupo de Trabajo de Insuficiencia Cardiaca Aguda de la Sociedad Española de Urgencias y Emergencias (Grupo ICA-SEMES).
DOI
Quote
Llorens P. Sodium-glucose co-transporter 2 inhibitors: their role in heart failure management in Emergency Departments. Rev Esp Urg Emerg. 2023;2:164–9
Summary
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are effective in patients with heart failure across the ejection fraction (EF) spectrum. These drugs have been shown to reduce admissions for heart failure and emergency department visits. They also reduce arrhythmias and lower cardiovascular and all-cause mortality. Current evidence suggests that SGLT2 inhibitors should be prescribed early in heart failure regardless of the patient’s EF or the presence or not of diabetes mellitus. This review discusses the benefits of SGLT2 inhibitors in heart failure with reduced, slightly reduced, or preserved EF, given that these drugs clearly lower morbidity and mortality when started early. Available evidence supports their use in acute or chronic heart failure. Tolerance is good and there is no need for titration.
More articles by the authors
